Overview

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Status:
Completed
Trial end date:
2018-09-30
Target enrollment:
Participant gender:
Summary
To compare the effects and safety of Anlotinib with placebo in patients with Medullary Thyroid Carcinoma.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd